Ophthalmic surgery and lasers · 1998
Photodynamic therapy for corneal neovascularization.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Primbs G B, Casey R, Wamser K, Snyder W J, Crean D H
Аннотация
BACKGROUND AND OBJECTIVE: Photodynamic therapy with tin ethyl etiopurpurin (SnET2) was evaluated as a treatment modality for rat corneal neovascularization.
MATERIALS AND METHODS: Escalating light doses at 664 nm were applied focally to corneal neovascularization in rats 10 minutes following an intravenous injection of SnET2 using a low-power diode laser. Controls consisted of light-only and drug-only treatments. Clinical, angiographic, and histopathologic evaluations were performed on the animals up to 28 days after drug and/or light treatment.
RESULTS: A drug and light dose-response was seen in producing neovessel closure. In animals treated with SnET2 and the highest light dose (25 J/cm2), all eyes showed occlusion at every follow-up evaluation up to 28 days. Control eyes demonstrated progressive disease at all time points.
CONCLUSIONS: Photodynamic therapy appears to be safe and effective for eliciting prolonged (> 28 days) occlusion of corneal neovascularization in the rat model with minimal side effects and good clinical outcomes.
MATERIALS AND METHODS: Escalating light doses at 664 nm were applied focally to corneal neovascularization in rats 10 minutes following an intravenous injection of SnET2 using a low-power diode laser. Controls consisted of light-only and drug-only treatments. Clinical, angiographic, and histopathologic evaluations were performed on the animals up to 28 days after drug and/or light treatment.
RESULTS: A drug and light dose-response was seen in producing neovessel closure. In animals treated with SnET2 and the highest light dose (25 J/cm2), all eyes showed occlusion at every follow-up evaluation up to 28 days. Control eyes demonstrated progressive disease at all time points.
CONCLUSIONS: Photodynamic therapy appears to be safe and effective for eliciting prolonged (> 28 days) occlusion of corneal neovascularization in the rat model with minimal side effects and good clinical outcomes.